Clearstead Advisors
CRVS icon

Clearstead Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Clearstead Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50
Closed -$732 – 3673
2026
Q1 		$732 Sell
50
-153
-75% -$2.44K ﹤0.01% 2080
2025
Q4 		$1.57K Buy
+203
New +$1.6K ﹤0.01% 2172

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Clearstead Advisors's CRVS Position: Q2 2026 in Review

Clearstead Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 50 shares — an estimated $732 sold.

Clearstead Advisors first reported a position in CRVS in Q4 2025 and held it in 2 quarters. The position peaked at $1.57K in Q4 2025. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Clearstead Advisors reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Clearstead Advisors sold 50 Corvus Pharmaceuticals shares in Q2 2026, an estimated $732.
  • Clearstead Advisors first reported a position in Corvus Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Clearstead Advisors's Corvus Pharmaceuticals position peaked at $1.57K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.